The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00791076|
Recruitment Status : Terminated (PI left JHU)
First Posted : November 14, 2008
Results First Posted : July 12, 2017
Last Update Posted : July 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 1||Drug: Placebo Drug: Pancreatic Polypeptide (PP)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 (Auto-immune) and Post-pancreatectomy Diabetic Patients|
|Actual Study Start Date :||October 2007|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||June 2010|
Placebo Comparator: Saline Placebo
2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
Other Name: Saline
Active Comparator: Pancreatic Polypeptide
Drug: Pancreatic Polypeptide (PP)
2pmol/kg-1/min-1 PP infused continuously over 72 hours.
Other Name: PP
- Total Amount of Insulin Administered While on Placebo/PP. [ Time Frame: 2 years ]Glucose values and the pattern of glycemic excursions over the 72 hour test period.
- Frequency of Hypoglycemia Defined as < 60 mg/dl. [ Time Frame: 72 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00791076
|United States, Maryland|
|Johns Hopkins Bayview Medical Center|
|Baltimore, Maryland, United States, 21224|
|Principal Investigator:||Dariush Elahi, PhD||Johns Hopkins University|